drugset / Trial / NCT04356508
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
Timeline
- Start
- 2020-04-14
- Primary completion
- 2020-06-30
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 0.3 mg/kg | — |